Literature DB >> 12586620

GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Johann K Hitzler1, Joseph Cheung, Yue Li, Stephen W Scherer, Alvin Zipursky.   

Abstract

Children with constitutional trisomy 21 (Down syndrome) have an approximately 500-fold increased risk of developing acute megakaryoblastic leukemia (AMKL), a form of acute myeloid leukemia. Unique to newborn infants with Down syndrome is a transient leukemia (TL), also referred to as transient myeloproliferative syndrome, that undergoes spontaneous remission in the majority of cases but in approximately 20% is followed by AMKL later in life. Recently mutations of the gene encoding the hematopoietic transcription factor GATA1 were shown to be specific for AMKL of Down syndrome. Here, we demonstrate that GATA1 mutations are present in blasts of TL and show the identical GATA1 mutation in sequential samples collected from a patient during TL and subsequent AMKL. These findings suggest a model of malignant transformation in Down syndrome AMKL in which GATA1 mutations are an early event and AMKL arises from latent TL clones following initial apparent remission.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586620     DOI: 10.1182/blood-2003-01-0013

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome.

Authors:  Sabine Dormann; Marcus Krüger; Roland Hentschel; Regina Rasenack; Brigitte Strahm; Udo Kontny; Charlotte Niemeyer
Journal:  Eur J Pediatr       Date:  2004-04-28       Impact factor: 3.183

Review 2.  GATA transcription factors in hematologic disease.

Authors:  Alan B Cantor
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

3.  Purification of leukemic blast cells from blood smears using laser microdissection.

Authors:  Hidemasa Matsuo; Shuichi Shiga; Tsuyoshi Imai; Yasuhiko Kamikubo; Tsutomu Toki; Kiminori Terui; Etsuro Ito; Souichi Adachi
Journal:  Int J Hematol       Date:  2017-04-13       Impact factor: 2.490

4.  Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.

Authors:  Marius Flasinski; Kira Scheibke; Martin Zimmermann; Ursula Creutzig; Katarina Reinhardt; Femke Verwer; Valerie de Haas; Vincent H J van der Velden; Christine von Neuhoff; C Michel Zwaan; Dirk Reinhardt; Jan-Henning Klusmann
Journal:  Blood Adv       Date:  2018-07-10

5.  GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.

Authors:  Su Han Lum; Soo Sin Choong; Shekhar Krishnan; Zulqarnain Mohamed; Hany Ariffin
Journal:  Singapore Med J       Date:  2016-06       Impact factor: 1.858

Review 6.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

7.  Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21.

Authors:  Anindita Roy; Gillian Cowan; Adam J Mead; Sarah Filippi; Georg Bohn; Aristeidis Chaidos; Oliver Tunstall; Jerry K Y Chan; Mahesh Choolani; Phillip Bennett; Sailesh Kumar; Deborah Atkinson; Josephine Wyatt-Ashmead; Ming Hu; Michael P H Stumpf; Katerina Goudevenou; David O'Connor; Stella T Chou; Mitchell J Weiss; Anastasios Karadimitris; Sten Eirik Jacobsen; Paresh Vyas; Irene Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

8.  Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.

Authors:  Hirokazu Kanegane; Sayaka Watanabe; Keiko Nomura; Gang Xu; Etsuro Ito; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

9.  Transient leukaemia: leukaemia or leukaemoid? A diagnostic dilemma.

Authors:  Nisha Marwah; Shilpi Modi; Veena Gupta; Sumiti Gupta; Gajender Singh; Rajeev Sen
Journal:  Indian J Hematol Blood Transfus       Date:  2011-07-12       Impact factor: 0.900

10.  Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2.

Authors:  Kamaleldin E Elagib; Mang Xiao; Isa M Hussaini; Lorrie L Delehanty; Lisa A Palmer; Frederick K Racke; Michael J Birrer; Shanmugasundaram Ganapathy-Kanniappan; Ganapath Shanmugasundaram; Michael A McDevitt; Adam N Goldfarb
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.